TY - JOUR
T1 - In transit metastases in children, adolescents and young adults with localized rhabdomyosarcoma of the distal extremities
T2 - Analysis of the EpSSG RMS 2005 study
AU - Terwisscha van Scheltinga, C. E.J.
AU - Wijnen, M. H.W.A.
AU - Martelli, H.
AU - Guerin, F.
AU - Rogers, T.
AU - Craigie, R. J.
AU - Burrieza, G. Guillén
AU - Dall'Igna, P.
AU - De Corti, F.
AU - Smeulders, N.
AU - van Rijn, R. R.
AU - Fajardo, R. Dávila
AU - Mandeville, H. C.
AU - Zanetti, I.
AU - Coppadoro, B.
AU - Minard-Colin, V.
AU - Jenney, M.
AU - Bisogno, G.
AU - van Noesel, M. M.
AU - van der Steeg, A. F.W.
AU - Merks, J. H.M.
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/7/1
Y1 - 2022/7/1
N2 - In-transit metastases (ITM) are defined as metastatic lymph nodes or deposits occurring between the primary tumor and proximal draining lymph node basin. In extremity rhabdomyosarcoma (RMS), they have rarely been reported. This study evaluates the frequency, staging and survival of patients with ITM in distal extremity RMS. Methods: Patients with extremity RMS distal to the elbow or knee, enrolled in the EpSSG RMS 2005 trial between 2005 and 2016 were eligible for this study. Results: One hundred and nine distal extremity RMS patients, with a median age of 6.2 years (range 0–21 years) were included. Thirty seven of 109 (34%) had lymph node metastases at diagnosis, 19 of them (51%) had ITM, especially in lower extremity RMS. 18F-FDG-PET/CT detected involved lymph nodes in 47% of patients. In patients not undergoing 18F-FDG-PET/CT lymph node involvement was detected in 22%. The 5-yr EFS of patients with ITM vs proximal lymph nodes vs combined proximal and ITM was 88.9% vs 21.4% vs 20%, respectively (p = 0.01) and 5-yr OS was 100% vs 25.2% vs 15%, respectively (p = 0.003). Conclusion: Our study showed that in-transit metastases constituted more than 50% of all lymph node metastases in distal extremity RMS. 18F-FDG-PET/CT improved nodal staging by detecting more regional and in-transit metastases. Popliteal and epitrochlear nodes should be considered as true (distal) regional nodes, instead of in-transit metastases. Biopsy of these nodes is recommended especially in distal extremity RMS of the lower limb. Patients with proximal (axillary or inguinal) lymph node involvement have a worse prognosis.
AB - In-transit metastases (ITM) are defined as metastatic lymph nodes or deposits occurring between the primary tumor and proximal draining lymph node basin. In extremity rhabdomyosarcoma (RMS), they have rarely been reported. This study evaluates the frequency, staging and survival of patients with ITM in distal extremity RMS. Methods: Patients with extremity RMS distal to the elbow or knee, enrolled in the EpSSG RMS 2005 trial between 2005 and 2016 were eligible for this study. Results: One hundred and nine distal extremity RMS patients, with a median age of 6.2 years (range 0–21 years) were included. Thirty seven of 109 (34%) had lymph node metastases at diagnosis, 19 of them (51%) had ITM, especially in lower extremity RMS. 18F-FDG-PET/CT detected involved lymph nodes in 47% of patients. In patients not undergoing 18F-FDG-PET/CT lymph node involvement was detected in 22%. The 5-yr EFS of patients with ITM vs proximal lymph nodes vs combined proximal and ITM was 88.9% vs 21.4% vs 20%, respectively (p = 0.01) and 5-yr OS was 100% vs 25.2% vs 15%, respectively (p = 0.003). Conclusion: Our study showed that in-transit metastases constituted more than 50% of all lymph node metastases in distal extremity RMS. 18F-FDG-PET/CT improved nodal staging by detecting more regional and in-transit metastases. Popliteal and epitrochlear nodes should be considered as true (distal) regional nodes, instead of in-transit metastases. Biopsy of these nodes is recommended especially in distal extremity RMS of the lower limb. Patients with proximal (axillary or inguinal) lymph node involvement have a worse prognosis.
KW - Extremity
KW - In-transit metastases
KW - Lymph nodes
KW - Pediatric
KW - Rhabdomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=85126552421&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2022.03.001
DO - 10.1016/j.ejso.2022.03.001
M3 - Article
C2 - 35307252
AN - SCOPUS:85126552421
SN - 0748-7983
VL - 48
SP - 1536
EP - 1542
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 7
ER -